Insilico Biotechnology AG announces that their Representative Office in Singapore has now evolved into a subsidiary. This step will enable the company to address the unique requirements of the growing biopharmaceutical market in the APAC region. Insilico’s predictive solutions and Digital Twins for biomanufacturing enhance the capability of biopharmaceutical companies to provide high quality biologics at reduced cost and at accelerated timelines. 

Klaus Mauch, CEO of Insilico says that “It is our aim to be a partner for both process development and manufacturing teams in the APAC biopharmaceutical industry as they strive to reduce the cost of goods and provide high quality biologics to billions of people. We think that the digitalization of the biofactory will play an important role in achieving the ambitious goal of producing biologics such as recombinant antibodies at less than 10$/g.” The director of the newly incorporated Singapore subsidiary, Dr. Shilpa Nargund adds "The journey from planning the Singapore subsidiary on a phone call in early 2018 to opening a representative office in 2019 and to finally founding the subsidiary in 2020 has been most rewarding. Even more exciting is the fact that our team in Singapore has grown to include highly skilled data scientists. We expect the team to grow further as our APAC order backlog is growing fast."